The diagnostic efficiencies of TrxR activity, as well as those of the existing NSCLC clinical biomarkers NSE, Cyfra21-1, CA19-9, and CEA were evaluated and compared as a means of differentiating between patients with NSCLCs, BLDs, and healthy controls. The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.